Skip to main content

Mutanome Engineered RNA Immuno-Therapy

Objective

The Mutanome Engineered RNA Immuno-Therapy (MERIT) project aims to clinically translate and industrially validate a pioneering RNA-based immunotherapy approach to target the individual tumour antigen signature. MERIT focuses on previous inventions, fits into the overall business and innovation needs of the partners, and addresses triple-negative breast cancer patients with high medical need. The MERIT concept, including patents and potential products, was developed using EU FP6 funding. The innovative therapeutics will pave the way for generation of scientific knowledge and technologies and will stimulate the development of new products, tools, patents, and innovative marketable applications.
The concept behind MERIT is to implement a highly innovative Next-Generation-Immunotherapy drug platform enabling Next–Generation-Sequencing-guided stratified medicine and clinical-grade individualized RNA vaccines. Every patient’s tumour expresses many shared tumour-specific antigens and bears a highly individual molecular “signature” comprising 10’s to 100’s of non-synonymous mutations, many of which are immunogenic. We will use clinical-grade RNA to produce a) a warehouse of therapeutic vaccines targeting shared antigens and b) custom therapeutic vaccines targeting patient-specific mutations. Upon success, partner BioNTech will move the therapeutics to advanced clinical trials and commercial applications for the benefit of triple negative breast cancer patients and other solid tumours.

Field of science

  • /natural sciences/biological sciences/genetics and heredity/mutation
  • /social sciences/economics and business
  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

BIONTECH AG
Address
Holderlinstrasse 8
55131 Mainz
Germany
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 4 456 750
Administrative Contact
Ugur Sahin (Prof.)

Participants (4)

INSTITUT GUSTAVE ROUSSY
France
EU contribution
€ 453 750
Address
Rue Camille Desmoulins 39
94805 Villejuif
Activity type
Research Organisations
Administrative Contact
Arnauld Forest (Mr.)
VRIJE UNIVERSITEIT BRUSSEL
Belgium
EU contribution
€ 401 250
Address
Pleinlaan 2
1050 Brussel
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Nik Claesen (Mr.)
UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 315 000
Address
Ramistrasse 71
8006 Zürich
Activity type
Other
Administrative Contact
Steve Pascolo (Dr.)
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 337 500
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Pirkko Boox (Mrs.)